Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, et al. Relative dose intensity over the first four weeks of lenvatinib therapy is a
factor of favorable response and overall survival in patients with unresectable
hepatocellular carcinoma. PLoS One 2020;15:e0231828.
PMID: 32310967